Vizimpro patent expiration 2026?

Vizimpro is the brand name for dacomitinib, an EGFR/HER family inhibitor. Patent expiration dates are not a single global date—they vary by country and by patent family (composition patent, use patents, formulation patents, etc.), and can also be affected by regulatory data exclusivity and patent term extensions.

If you want a precise answer for 2026, I’d need the jurisdiction you care about. In the meantime, here’s how you can check accurately:

- US: Look up Vizimpro (dacomitinib) in the FDA Orange Book to see which patents and exclusivities are listed and their expiration dates. Also check the USPTO Patent Center for the actual patent life and any term adjustments.

- Global: Use Google Patents or the EPO’s Espacenet to review the dacomitinib patent families (search for “dacomitinib” and Pfizer). Note the earliest priority date and any term extensions.

- Other protections: After the primary patents expire, there may still be other patents (e.g., use or formulation patents) and regulatory data exclusivity that can affect when generics can enter.

If you tell me the country or region you’re interested in (US, EU, others) I can give a more targeted summary or walk you to the exact expiration dates in that jurisdiction. And I can help interpret any patent numbers you find.